Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Bunkyo-ku, Tokyo, 113-8421, Japan.
Surg Endosc. 2019 Jun;33(6):2008-2014. doi: 10.1007/s00464-018-06642-5. Epub 2019 Jan 2.
Duodenal neuroendocrine tumors (NETs) measuring ≤ 10 mm in diameter that are confined to the submucosal layer without metastasis are suitable for endoscopic treatment. We previously reported the efficacy and safety of endoscopic submucosal resection with a ligation device (ESMR-L) for duodenal NETs. In order to make the procedure simpler, we attempted ESMR-L without submucosal injection. The aim of this study was to evaluate the efficacy of ESMR-L without injection for duodenal NETs.
A total of 12 patients with small (≤ 10 mm) sporadic duodenal NETs were treated via endoscopic resection at the National Cancer Center Hospital East between December 2010 and May 2018. All patients were evaluated via endoscopy and endoscopic ultrasound, and abdominal computed tomography was performed to rule out metastatic lesions. The patients' characteristics, clinical courses, and complications, such as perforation and bleeding, were retrospectively assessed. We examined the correlation between ESMR-L with or without submucosal saline injection and clinicopathological parameters.
The median procedural time for ESMR-L was 13 min. All lesions invaded the submucosal layer, and the histological diagnoses were classified as NET G1 in 11 lesions and NET G2 in one lesion. En bloc resection and complete resection were achieved in 12 and 11 lesions, respectively. The postoperative duration of hospital stay was 4 days. At the median follow-up of 17 months, there was no incidence of local recurrence or distant metastasis. Perforation and intraoperative bleeding were not observed. However, delayed bleeding was found in one patient. ESMR-L without submucosal injection required a significantly shorter procedural time than ESMR-L with submucosal saline injection (10 min vs. 15 min, respectively; p = 0.007).
ESMR-L is safe and effective. Particularly, ESMR-L without submucosal injection could be used to treat these NETs safely within a short period of time.
直径≤10mm 且局限于黏膜下层、无转移的十二指肠神经内分泌肿瘤(NET)适合内镜治疗。我们之前报道过使用结扎装置的内镜黏膜下剥离术(ESMR-L)治疗十二指肠 NET 的疗效和安全性。为了使操作更简单,我们尝试了不进行黏膜下注射的 ESMR-L。本研究旨在评估不注射黏膜下层行 ESMR-L 治疗十二指肠 NET 的疗效。
2010 年 12 月至 2018 年 5 月,在国立癌症中心医院东部分别对 12 例直径较小(≤10mm)的散发性十二指肠 NET 患者进行内镜下切除。所有患者均通过内镜和内镜超声进行评估,并进行腹部计算机断层扫描以排除转移病灶。回顾性评估患者的特征、临床病程以及穿孔和出血等并发症。我们还研究了 ESMR-L 是否进行黏膜下盐水注射与临床病理参数之间的相关性。
ESMR-L 的中位操作时间为 13 分钟。所有病变均侵犯黏膜下层,组织学诊断为 11 例 NET G1 和 1 例 NET G2。整块切除和完全切除分别在 12 例和 11 例中实现。术后住院时间中位数为 4 天。中位随访 17 个月时,无局部复发或远处转移。未观察到穿孔和术中出血,但有 1 例发生延迟性出血。不进行黏膜下注射的 ESMR-L 所需的操作时间明显短于进行黏膜下盐水注射的 ESMR-L(分别为 10 分钟和 15 分钟;p=0.007)。
ESMR-L 是安全有效的。特别是,不进行黏膜下注射的 ESMR-L 可在短时间内安全地用于治疗这些 NET。